Magnitude of benefit greater early in patients with multivessel disease, but it continues to grow over time in all patients taking the drug
The use of evolocumab reduced the rate of major adverse cardiovascular events (MACE) in patients with known atherosclerotic coronary artery disease (CAD), regardless of whether they had multivessel CAD, but the drug’s benefit was larger and occurred earlier in patients with multivessel disease, a long-term study shows.